2. Protein Tyrosine Kinase/RTK
  3. c-Fms
  4. Trabikibart

Trabikibart  (Synonyms: CSL311)

Art. -Nr.: HY-P990094 Reinheit: 99.17%
COA
SDS
Technical Support

Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 2643974-98-3

Größe Preis Verfügbarkeit Menge
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
50 mg   Angebot einholen  
100 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Trabikibart Related Antibodies

Top Publications Citing Use of Products

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps[1][2][3][4].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

CSF2Rb/CD131
In Vitro

Trabikibart potently blocks human βc receptor signalling with high potency[1].
Trabikibart binds to the Site 2 region of the soluble βc-receptor subunit with a KD of 100 pM, blocking IL-3, IL-5, and GM-CSF binding[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Trabikibart Related Antibodies
In Vivo

Trabikibart (3-50 mg/kg; i.v.; single dose) dose-dependently reduces LPS-induced myeloid cell expansion, lung inflammation, oedema, netosis, and respiratory dysfunction in hβcTg mice, with maximal efficacy observed at the 50 mg/kg dose for most endpoints[1].
Trabikibart (50 mg/kg; i.v.; single dose; administered day 4 post-infection) reduces systemic and lung myeloid inflammation, haemorrhage, and pro-inflammatory cytokine expression in IAV-infected hβcTg mice without compromising viral clearance or anti-viral immune cell function[1].
Trabikibart (50 mg/kg; i.v.; twice) potently inhibits mixed granulocytic inflammation, airway hyperresponsiveness, and airway fibrosis in an acute steroid-resistant asthma model, reducing inflammation scores and collagen deposition while normalizing lung function and gene expression[4].
Trabikibart (50 mg/kg; i.v.; once weekly; 4 weeks) effectively inhibits chronic allergen-induced airway inflammation, impaired lung function, and remodeling, normalizing fibrosis-associated extracellular matrix gene expression and outperforming single cytokine-targeting therapies[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: hβcTg mice (8-to-12-week-old male and female; endogenous mouse βc and βIL-3 receptors knocked out, replaced with human βc receptor)[1]
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration: i.v.; single dose
Result: Dose-dependently reduced peak blood neutrophil numbers, with levels declining to control values at the 10 mg/kg dose.
Maximally reduced peak blood monocyte numbers at the 50 mg/kg dose.
Dose-dependently reduced lung MPO activity, with maximal decrease observed at the 50 mg/kg dose.
Dose-dependently decreased peak BAL neutrophil numbers, with maximal reduction at the 10 mg/kg dose.
Significantly improved peripheral blood oxygen saturation (SpO2) levels at 24 and 72 hours post-LPS challenge with a single 50 mg/kg dose.
Significantly reduced lung injury scores (assessed by vascular, bronchiole, and alveolar inflammation).
Reduced BAL fluid total protein levels (a marker of oedema).
Significantly reduced peak BAL MPO activity and dsDNA levels (markers of netosis).
Animal Model: hβcTg mice (8-to-12-week-old male and female; endogenous mouse βc and βIL-3 receptors knocked out, replaced with human βc receptor)[1]
Dosage: 50 mg/kg
Administration: i.v.; single dose; administered day 4 post-infection
Result: Did not alter IAV-induced body weight loss or lung viral load.
Significantly reduced elevated blood monocyte, blood neutrophil, and blood haemoglobin levels induced by IAV infection.
Significantly reduced BAL neutrophil and macrophage numbers.
Reduced lung haemorrhagic regions.
Significantly reduced lung neutrophils, alveolar macrophages, exudative macrophages, monocytes, and eosinophils; did not alter lung NK cells, NKT cells, regulatory T cells, CD4 T cells, and CD8 T cell numbers.
Significantly reduced lung Ccl2, Ccl24, and Il1α levels; did not alter Cxcl1, Cxcl10, Il6, Ifnb, Ifng, or Ifnl2/3 levels.
Animal Model: human common b transgenic (hbcTg) mice (8- to 12-week-old female, devoid of murine bc/bIL-3 receptors, expressing human bc receptor, acute steroid-resistant asthma model)[4]
Dosage: 50 mg/kg
Administration: i.v.; twice (day 8 and day 10)
Result: Significantly reduced blood monocyte and neutrophil counts.
Reduced bronchoalveolar lavage (BAL) cell infiltration of macrophages, neutrophils, and eosinophils.
Reduced lung tissue infiltration of neutrophils, eosinophils, alveolar macrophages, and interstitial macrophages.
Decreased BAL markers of neutrophil extracellular traps (dsDNA, myeloperoxidase activity) and lung injury (total protein, lactate dehydrogenase).
Suppressed TH2/TH17 cytokines (Il4, Il13, Il17) and T-cell chemokine Ccl17 while preserving TH1 cytokines (Ifng, Il12b).
Abolished methacholine-induced airway hyperresponsiveness.
Rescued restrictive lung function abnormalities (partial restoration of pressure-volume curve, quasi-static compliance, and respiratory system elastance).
Reduced peribronchiolar/alveolar inflammation score and airway collagen deposition (Masson trichrome-positive area fraction).
Normalized Col1a1 gene expression to control levels.
Animal Model: human common b transgenic (hbcTg) mice (8- to 12-week-old female, devoid of murine bc/bIL-3 receptors, expressing human bc receptor, chronic asthma model)[4]
Dosage: 50 mg/kg
Administration: i.v.; once weekly; 4 weeks
Result: Rescued ASP-induced restrictive lung function abnormalities (normalized respiratory system elastance, static compliance, and pressure-volume curves).
Reduced lung inflammation score.
Decreased airway collagen deposition (Masson trichrome-positive area fraction).
Normalized ASP-induced global gene expression changes, including downregulating 268 ASP-upregulated genes.
Suppressed hallmark inflammatory response gene signatures.
Inhibited TH2 and IL-17 signaling pathways.
Normalized extracellular matrix (ECM) gene expression (including reducing ASP-upregulated ECM regulators [Mmp12, Mmp13, Tgfb1, Thbs4] and matrisome-associated genes).
Shifted collagen gene expression from fibril-forming to non-fibril-forming species.
Reduced both BAL eosinophils and neutrophils (unlike single cytokine blockers targeting only eosinophils or neutrophils).
Gene ID

1439  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molekulargewicht

144.66 kDa

CAS. Nr.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Trabikibart]
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Immobilized CD131 Protein, Human can bind Trabikibart. The EC50 for this effect is 14.31 ng/mL.
  • Loaded Trabikibart on ProA biosensor, can bind CD131 Protein, Human (HEK293, His, HY-P75608) with an affinity constant of 9.994E-10 M as determined in BLI assay.
Reinheit & Dokumentation

Purity: 99.17%

SDS (251 KB)

COA (232 KB) SDS-PAGE (71 KB) SEC-HPLC (129 KB)

Inhibitory Antibodies User Guide (603 KB)
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Trabikibart Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Trabikibart2643974-98-3CSL311CSL 311CSL-311c-FmsCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1Racute respiratory distress syndromecommon beta (βc) receptorRag2?/?Il2rg?/?hIL-3/GM-CSF knock-in micehuman βc transgenic miceGM-CSFviral pneumoniahβcTg miceIL-5human nasal polypsIL-3Inhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Trabikibart
Art. -Nr.:
HY-P990094
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.